Stryker Lifts Organic Sales Outlook After 1Q Rise
By Ben Glickman
Stryker raised its full-year forecast for organic sales growth after its first-quarter profit and revenue both rose more than expected.
The Portage, Mich.-based medical technology company reported a profit of $788 million, or $2.05 a share, in the quarter ended March 31, compared with a profit of $592 million, or $1.54 a share, a year earlier. Analysts polled by FactSet expected a per-share profit of $1.99.
Stripping out certain one-time items, the company posted an adjusted per-share profit of $2.50, ahead of the $2.36 expected by analysts surveyed by FactSet.
Revenue rose 9.7% to $5.24 billion, beating the $5.1 billion expected by analysts polled by FactSet.
Stryker's organic sales were up 10% in the period, almost all of which was from increases to sales volume. Analysts polled by FactSet expected organic sales to be up about 7.3%.
The company's MedSurg and Neurotechnology sales were up 11.5%, while orthopaedics and spine sales had slower growth.
The company said it expects organic sales to be up 8.5% to 9.5% for 2024, compared to its previous outlook for a 7.5% to 9% increase.
Stryker also lifted its full-year forecast for adjusted per-share earnings to $11.85 to $12.05, compared with a previous guidance range of $11.70 to $12.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 30, 2024 16:34 ET (20:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now